

## Financial Tear Sheet


### Corporate Profile

Amgen, the world's largest biotechnology company, uses science and innovation in an effort to dramatically improve people's lives. Amgen aspires to be the world's best human therapeutics company.

Our researchers harness the powerful tools of cellular and molecular biology and medicinal chemistry to discover, develop and commercialize naturally occurring proteins, antibodies and small molecules, with the goal of extending the reach of science to unleash the body's own powerful therapeutic responses. Amgen's research and product development programs aim to help patients in four critical areas: nephrology, hematology and oncology, bone and inflammation, neurology and endocrinology.

### Stock Performance

AMGN (COMMON STOCK)	
Exchange	NASDAQ (US Dollar)
Price	\$203.88
Change (%)	▲ 1.96 (0.97%)
Volume	3,048,434
52 Week Low	\$163.31
Market Cap	\$129,916,259,467
Rolling EPS	3.84
PE Ratio	53.0938
Shares Outstanding	637,219,244



Data as of 01/18/19 4:15 p.m. ET

## Recent Headlines

01/22/19

European Commission Approves BLINCYTO® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia

01/16/19

Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY™ (romosozumab)

01/08/19


EVENITY™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture

## Upcoming Events

DATE	TITLE
01/29/19 2:00 p.m. PT	Q4 2018 Amgen Earnings Conference Call

## Analyst Estimates / Ratings

Mean Recommendation: **2.3**



Unable to fulfill request.

## SEC Filings

FILING DATE	FORM
01/14/19	5
12/28/18	SC 13G/A
12/10/18	4
12/03/18	4

## Financial Reports

Q4 2017 Financial Results

## Presentations

01/08/19 37th Annual J.P. Morgan Healthcare  
Conference Presentation

*Data provided by Nasdaq. Minimum 15 minutes delayed.*